Comparison of gliclazide with insulin as initial treatment modality in newly diagnosed type 2 diabetes

Diabetes Technology & Therapeutics
Satish T ChandraAriachery C Ammini

Abstract

This study was designed to compare effectiveness and remission rate between gliclazide and insulin as initial treatment in newly diagnosed, drug-naive patients with type 2 diabetes. Newly diagnosed, drug-naive subjects with type 2 diabetes having mean fasting blood glucose >200 mg/dL were enrolled into either of two groups (gliclazide or insulin). The former received gliclazide modified-release 60 mg daily, while the insulin group received 16 units of premixed insulin as two divided doses along with medical nutrition therapy. Premeal blood glucose was monitored, and the dose was adjusted accordingly. Glycosylated hemoglobin (HbA1c), lipid profile, and postmeal C-peptide were estimated at baseline and 6 months. Remission was defined as euglycemia off drug for a minimum duration of 1 month. Baseline and 6-month blood glucose, HbA1c, and lipid profile were comparable between groups. Blood glucose levels normalized in 2-6 weeks in both groups. At 6 months, one of 30 (3.33%) in the gliclazide group and 24 of 30 (80%) in the insulin group were in remission. Ten of 16 (62.5%) in the insulin group and one of 20 (.5%) in the gliclazide group continued to maintain euglycemia off all pharmacological treatment at 12 months. At 6 months, C-...Continue Reading

References

Aug 1, 1989·Diabetic Medicine : a Journal of the British Diabetic Association·B H WolffenbuttelL Verschoor
May 1, 1983·Diabetologia·J RahierJ C Henquin
May 1, 1995·Diabetes Research and Clinical Practice·T KayashimaM Shichiri
Jul 1, 1995·Diabetes·G E UmpierrezL S Phillips
Feb 13, 2001·Diabetic Medicine : a Journal of the British Diabetic Association·S I McFarlaneM A Banerji
Aug 10, 1957·British Medical Journal·M F CROWLEYA BLOOM
Aug 10, 1957·British Medical Journal
Aug 8, 1957·The New England Journal of Medicine·R HARWOOD
Mar 1, 1958·Diabetes·F B PECKF B PECK
May 1, 1959·Diabetes·L J STUTMAN, J D HAYES
Aug 1, 1961·Annals of Internal Medicine·J J HINES, D L KESSLER
Oct 17, 1959·British Medical Journal·A BLOOM
Apr 28, 2004·Diabetes Care·Edmond A RyanClarissa Wallace
May 11, 2004·Current Diabetes Reports·Mary Ann Banerji
Oct 16, 2004·The Journal of Clinical Endocrinology and Metabolism·Kathrin MaedlerMarc Y Donath
Apr 23, 2005·Nature·Alessandro PocaiLuciano Rossetti
Mar 8, 2006·Annals of Internal Medicine·Guillermo E UmpierrezAbbas E Kitabchi

❮ Previous
Next ❯

Citations

May 23, 2009·Diabetes Technology & Therapeutics·Deepti ChathurvediAriachery C Ammini
Mar 2, 2011·Diabetes Technology & Therapeutics·Saptarshi BhattacharyaSadanand Dwivedi
Jun 22, 2013·Diabetes Technology & Therapeutics·David R Owens
Mar 21, 2009·Current Opinion in Endocrinology, Diabetes, and Obesity·Mayer B Davidson
Mar 10, 2009·Diabetes/metabolism Research and Reviews
Apr 19, 2013·Diabetes, Obesity & Metabolism·M MonamiE Mannucci
Sep 10, 2014·Diabetes/metabolism Research and Reviews·Jianping WengJeong-Taek Woo
Mar 23, 2017·The Journal of Clinical Endocrinology and Metabolism·Natalia McInnesHertzel C Gerstein
Jul 30, 2015·The Cochrane Database of Systematic Reviews·Bianca HemmingsenThomas P Almdal
Mar 21, 2009·Current Opinion in Endocrinology, Diabetes, and Obesity

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.